( June 24, 2025, 8:51 AM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel vacated a U.S. Patent Trial and Appeal Board (PTAB) decision to uphold a drugmaker’s patent on a molecule for use in gastrointestinal disorder medications, finding that the board erred in its analysis of whether the patent holder had shown that its patented product had “unexpected results” when considering whether the patent’s claims were rendered obvious by prior art references....